Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a ...

Adrian stated on our September conference call that a 1 point difference on this scale could mean the difference in one's ability ... And over the quarter, we've improved our formulary position on a ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Runway Growth Finance Third Quarter 2024 Earnings Conference Call.

Plus, Regen Projects presents "Profit & Loss" by Walead Beshty and Ami Paris takes over Alfred on Melrose Place The post ...

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s ...

When you buy through links on our articles, Future and its syndication partners may earn a commission.

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a ...

Forward-Looking Statements This press release contains "forward-looking” statements and information within the meaning of the ...

Arbutus has moved into Part 3 of this clinical trial which evaluates repeat dosing of AB-101 for 28 days in patients with cHBV and expects to report preliminary data in the first half of next year.